Retinoic acid inducible gene-I (RIG-I) signaling of hepatic stellate cells inhibits hepatitis C virus replication in hepatocytes

Innate Immunity

Volumn 19, Issue 2, 2013, Pages 193-202

  Wang, Yizhong ^a,b   Ye, Li ^a   Wang, Xu ^b   Li, Jieliang ^b   Song, Li ^b   Ho, Wenzhe ^a,b  

^a WUHAN UNIVERSITY   (China)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatic stellate cells; hepatitis C virus; interferon; interferon stimulated genes; retinoic acid inducible gene I

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; INTERFERON REGULATORY FACTOR 7; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR 3;

ARTICLE; COCULTURE; HEPATITIS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; INNATE IMMUNITY; LIVER CELL; NONHUMAN; STELLATE CELL; VIRUS REPLICATION;

2',5'-OLIGOADENYLATE SYNTHETASE; ANTIBODIES, BLOCKING; CELL LINE, TRANSFORMED; COCULTURE TECHNIQUES; DEAD-BOX RNA HELICASES; GTP-BINDING PROTEINS; HEPACIVIRUS; HEPATIC STELLATE CELLS; HEPATITIS C; HEPATOCYTES; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; INTERFERON REGULATORY FACTOR-7; INTERFERON-BETA; INTERLEUKINS; RNA, DOUBLE-STRANDED; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 3; VIRUS REPLICATION;

HEPATITIS C VIRUS; ORTHOMYXOVIRIDAE;

EID: 84876382305     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425912460414     Document Type: Article

References (46)

1. Senoo H. Structure and function of hepatic stellate cells. Med Electron Microsc. 2004 ; 37: 3-15
2. Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis. 2001 ; 21: 311-335
3. Reynaert H, Thompson MG, Thomas T, Geerts A. Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut. 2002 ; 50: 571-581
4. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008 ; 134: 1655-1669
5. Winau F, Hegasy G, Weiskirchen R, Weber S, Cassan C, Sieling PA, et al. Ito cells are liver-resident antigen-presenting cells for activating T cell responses. Immunity. 2007 ; 26: 117-129
6. Ichikawa S, Mucida D, Tyznik AJ, Kronenberg M, Cheroutre H. Hepatic stellate cells function as regulatory bystanders. J Immunol. 2011 ; 186: 5549-5555
7. Kawai T, Akira S. Toll-like receptor and RIG-I-like receptor signaling. Ann N Y Acad Sci. 2008 ; 1143: 1-20
8. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol. 2006 ; 7: 131-137
9. Kumar A, Zhang J, Yu FS. Toll-like receptor 3 agonist poly(I:C)-induced antiviral response in human corneal epithelial cells. Immunology. 2006 ; 117: 11-21
10. Starace D, Galli R, Paone A, De Cesaris P, Filippini A, Ziparo E, et al. Toll-like receptor 3 activation induces antiviral immune responses in mouse sertoli cells. Biol Reprod. 2008 ; 79: 766-775
11. West J, Damania B. Upregulation of the TLR3 pathway by Kaposi's sarcoma-associated herpesvirus during primary infection. J Virol. 2008 ; 82: 5440-5449
12. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol. 2005 ; 17: 1-14
13. Janeway CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002 ; 20: 197-216
14. Rehwinkel J, Tan CP, Goubau D, Schulz O, Pichlmair A, Bier K, et al. RIG-I detects viral genomic RNA during negative-strand RNA virus infection. Cell. 2010 ; 140: 397-408
15. Fujita T, Onoguchi K, Onomoto K, Hirai R, Yoneyama M. Triggering antiviral response by RIG-I-related RNA helicases. Biochimie. 2007 ; 89: 754-760
16. Saito T, Owen DM, Jiang F, Marcotrigiano J, Gale M. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature. 2008 ; 454: 523-527
17. Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A. 2005 ; 102: 2992-2997
18. Li XD, Sun L, Seth RB, Pineda G, Chen ZJ. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci U S A. 2005 ; 102: 17717-17722
19. Xu L, Hui AY, Albanis E, Arthur MJ, O'Byrne SM, Blaner WS, et al. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut. 2005 ; 54: 142-151
20. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A. 2005 ; 102: 9294-9299
21. Ye L, Wang X, Wang S, Wang Y, Song L, Hou W, et al. CD56+ T cells inhibit hepatitis C virus replication in human hepatocytes. Hepatology. 2009 ; 49: 753-762
22. Yang JH, Lai JP, Douglas SD, Metzger D, Zhu XH, Ho WZ. Real-time RT-PCR for quantitation of hepatitis C virus RNA. J Virol Methods. 2002 ; 102: 119-128
23. Zhang T, Lin RT, Li Y, Douglas SD, Maxcey C, Ho C, et al. Hepatitis C virus inhibits intracellular interferon alpha expression in human hepatic cell lines. Hepatology. 2005 ; 42: 819-827
24. Katze MG, He Y, Gale M. Viruses and interferon: a fight for supremacy. Nat Rev Immunol. 2002 ; 2: 675-687
25. Foy E, Li K, Sumpter R, Jr., Loo YM, Johnson CL, Wang C, et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci U S A. 2005 ; 102: 2986-2991
26. Benedict CA, Ware CF. RIGing a virus trap. Nat Med. 2005 ; 11: 929-930
27. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol. 2006 ; 80: 4501-4509
28. Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H, et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology. 2006 ; 44: 896-906
29. Hou W, Wang X, Ye L, Zhou L, Yang ZQ, Riedel E, et al. Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. J Virol. 2009 ; 83: 3834-3842
30. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003 ; 4: 69-77
31. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. 2006 ; 131: 1887-1898
32. Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol. 2005 ; 79: 3851-3854
33. Zhang L, Jilg N, Shao RX, Lin W, Fusco DN, Zhao H, et al. IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J Hepatol. 2011 ; 55: 289-298
34. Pagliaccetti NE, Eduardo R, Kleinstein SH, Mu XJ, Bandi P, Robek MD. Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication. J Biol Chem. 2008 ; 283: 30079-30089
35. Zhu H, Butera M, Nelson DR, Liu C. Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication. Virol J. 2005 ; 2: 80-80
36. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009 ; 461: 399-401
37. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009 ; 41: 1100-1104
38. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009 ; 41: 1105-1109
39. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009 ; 461: 798-801
40. Miller DM, Klucher KM, Freeman JA, Hausman DF, Fontana D, Williams DE. Interferon lambda as a potential new therapeutic for hepatitis C. Ann N Y Acad Sci. 2009 ; 1182: 80-87
41. Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology. 52: 822-832
42. Bataller R, Paik YH, Lindquist JN, Lemasters JJ, Brenner DA. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology. 2004 ; 126: 529-540
43. Mazzocca A, Carloni V, Sciammetta S, Cordella C, Pantaleo P, Caldini A, et al. Expression of transmembrane 4 superfamily (TM4SF) proteins and their role in hepatic stellate cell motility and wound healing migration. J Hepatol. 2002 ; 37: 322-330
44. Mazzocca A, Sciammetta SC, Carloni V, Cosmi L, Annunziato F, Harada T, et al. Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells. J Biol Chem. 2005 ; 280: 11329-11339
45. Park O, Jeong WI, Wang L, Wang H, Lian ZX, Gershwin ME, et al. Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride. Hepatology. 2009 ; 49: 1683-1694
46. Radaeva S, Wang L, Radaev S, Jeong WI, Park O, Gao B. Retinoic acid signaling sensitizes hepatic stellate cells to NK cell killing via upregulation of NK cell activating ligand RAE1. Am J Physiol Gastrointest Liver Physiol. 2007 ; 293: G809 - G816